CTAD and ADDF Unite to Accelerate Alzheimer’s Innovation
NEW YORK, N.Y., June 16, 2026 The Clinical Trials on Alzheimer’s Disease (CTAD) Conference and the Alzheimer’s Drug Discovery...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
NEW YORK, N.Y., June 16, 2026 The Clinical Trials on Alzheimer’s Disease (CTAD) Conference and the Alzheimer’s Drug Discovery...
BRUSSELS, Belgium, June 17, 2026 UCB has announced the publication of two significant peer-reviewed studies in Brain Communications demonstrating...
